Literature DB >> 15169789

Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines.

Raudel Sandoval1, Jiaping Xue, Mark Pilkinton, Debra Salvi, Hiroaki Kiyokawa, Oscar R Colamonici.   

Abstract

The regulation of cell growth is one of the most important effects of type I interferons (IFNs). This response may involve a cytostatic effect or the induction of apoptosis depending on the cell context. Often the growth-inhibitory response of type I IFNs is studied in tumor cell lines carrying mutations of tumor suppressor genes, and therefore, the growth-inhibitory effect can be influenced by inactivation of these important regulators of cell proliferation. In this report, we explored the role of the ARF-p53 pathway in the growth-inhibitory effect of type I IFNs. We found that p53 is only induced in cells that express p14(ARF) (p19(ARF) in mouse cells). Surprisingly, mouse embryonal fibroblasts that are null for p19(ARF) or P53, even after transformation with oncogenic RAS, respond as well as wild type to the growth-inhibitory effect of type I IFNs. Similarly, human ARF(-/-) U2OS and P53(-/-) SAOS-2 cells show a significant decrease in cell proliferation. However, only SAOS-2 or U2OS reconstituted with inducible p14(ARF) undergo apoptosis in response to IFN beta treatment, and this effect was not inhibited by expression of dominant negative p53. These data suggest that (i) at least in specific cell types, the induction of apoptosis by type I IFNs requires an ARF pathway that is p53-independent and (ii) the cytostatic and pro-apoptotic effects of type I IFNs employ different pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15169789     DOI: 10.1074/jbc.M313830200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Antiviral action of the tumor suppressor ARF.

Authors:  María A García; Manuel Collado; César Muñoz-Fontela; Ander Matheu; Laura Marcos-Villar; Javier Arroyo; Mariano Esteban; Manuel Serrano; Carmen Rivas
Journal:  EMBO J       Date:  2006-09-07       Impact factor: 11.598

2.  Identification of De Novo Enhancers Activated by TGFβ to Drive Expression of CDKN2A and B in HeLa Cells.

Authors:  Yen-Ting Liu; Lin Xu; Lynda Bennett; Jared C Hooks; Jing Liu; Qinbo Zhou; Priscilla Liem; Yanbin Zheng; Stephen X Skapek
Journal:  Mol Cancer Res       Date:  2019-06-12       Impact factor: 5.852

Review 3.  Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-β gene transfer to cancer cells: An inducer of immunogenic cell death.

Authors:  Ruan F V Medrano; Aline Hunger; João P P Catani; Bryan E Strauss
Journal:  Oncoimmunology       Date:  2017-05-19       Impact factor: 8.110

Review 4.  Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Authors:  James F Curtin; Gwendalyn D King; Marianela Candolfi; Remy B Greeno; Kurt M Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

Review 5.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

6.  Interferon-inducible protein IFIXalpha1 functions as a negative regulator of HDM2.

Authors:  Yi Ding; Jin-Fong Lee; Hua Lu; Mong-Hong Lee; Duen-Hwa Yan
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

7.  A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis.

Authors:  Anthony J Scarzello; Ana L Romero-Weaver; Stephen G Maher; Timothy D Veenstra; Ming Zhou; Angel Qin; Raymond P Donnelly; Faruk Sheikh; Ana M Gamero
Journal:  Mol Biol Cell       Date:  2007-04-18       Impact factor: 4.138

8.  Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas.

Authors:  Regina I Jakacki; Eva Dombi; Seth M Steinberg; Stewart Goldman; Mark W Kieran; Nicole J Ullrich; Ian F Pollack; Anne Goodwin; Peter E Manley; Jason Fangusaro; Rudy Allen; Brigitte C Widemann
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

Review 9.  Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer.

Authors:  Bryan E Strauss; Gissele Rolemberg Oliveira Silva; Igor de Luna Vieira; Otto Luiz Dutra Cerqueira; Paulo Roberto Del Valle; Ruan Felipe Vieira Medrano; Samir Andrade Mendonça
Journal:  Clinics (Sao Paulo)       Date:  2018-09-06       Impact factor: 2.365

10.  NMI mediates transcription-independent ARF regulation in response to cellular stresses.

Authors:  Zengpeng Li; Jingjing Hou; Li Sun; Taoyong Wen; Liqin Wang; Xinmeng Zhao; Qingqing Xie; Si Qing Zhang
Journal:  Mol Biol Cell       Date:  2012-10-03       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.